High Prognostic Value of <sup>68</sup>Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry

In oligo-metastatic renal cell carcinoma (RCC), neither computed tomography (CT) nor bone scan is sensitive enough to detect small tumor deposits hampering early treatment and potential cure. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in the neo-vasculature o...

Full description

Bibliographic Details
Published in:Diagnostics
Main Authors: Donatello Gasparro, Maura Scarlattei, Enrico Maria Silini, Silvia Migliari, Giorgio Baldari, Veronica Cervati, Tiziano Graziani, Nicoletta Campanini, Umberto Maestroni, Livia Ruffini
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Subjects:
Online Access:https://www.mdpi.com/2075-4418/13/19/3082
_version_ 1850415145948282880
author Donatello Gasparro
Maura Scarlattei
Enrico Maria Silini
Silvia Migliari
Giorgio Baldari
Veronica Cervati
Tiziano Graziani
Nicoletta Campanini
Umberto Maestroni
Livia Ruffini
author_facet Donatello Gasparro
Maura Scarlattei
Enrico Maria Silini
Silvia Migliari
Giorgio Baldari
Veronica Cervati
Tiziano Graziani
Nicoletta Campanini
Umberto Maestroni
Livia Ruffini
author_sort Donatello Gasparro
collection DOAJ
container_title Diagnostics
description In oligo-metastatic renal cell carcinoma (RCC), neither computed tomography (CT) nor bone scan is sensitive enough to detect small tumor deposits hampering early treatment and potential cure. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in the neo-vasculature of numerous malignant neoplasms, including RCC, that can be targeted by positron emission tomography (PET) using PSMA-targeting radioligands. Our aim was to investigate whether PSMA-expression patterns of renal cancer in the primary tumor or metastatic lesions on immunohistochemistry (IHC) are associated with PET/CT findings using [<sup>68</sup>Ga]-PSMA-HBED-CC (PSMA-PET/CT). We then analyzed the predictive and prognostic role of the PSMA-PET/CT signal. In this retrospective single-center study we included patients with renal cancer submitted to PSMA-PET/CT for staging or restaging, with tumor specimens available for PSMA-IHC. Clinical information (age, tumor type, and grade) and IHC results from the primary tumor or metastases were collected. The intensity of PSMA expression at IHC was scored into four categories: 0: none; 1: weak; 2: moderate; 3: strong. PSMA expression was also graded according to the proportion of vessels involved (PSMA%) into four categories: 0: none; 1: 1–25%; 2: 25–50%; 3: >50%. The intensity of PSMA expression and PSMA% were combined in a three-grade score: 0–2 absent or mildly positive, 3–4 moderately positive, and 5–6 strongly positive. PSMA scores were used for correlation with PSMA-PET/CT results. Results: IHC and PET scans were available for the analysis in 26 patients (22 ccRCC, 2 papillary RCC, 1 chromophobe, 1 “not otherwise specified” RCC)<b>.</b> PSMA-PET/CT was positive in 17 (65%) and negative in 9 patients (35%). The mean and median SUVmax in the target lesion were 34.1 and 24.9, respectively. Reporter agreement was very high for both distant metastasis location and local recurrence (kappa 1, 100%). PSMA-PET detected more lesions than conventional imaging and revealed unknown metastases in 4 patients. Bone involvement, extension, and lesion number were greater than in the CT scan (median lesion number on PET/CT 3.5). The IHC PSMA score was concordant in primary tumors and metastases. All positive PSMA-PET/CT results (15/22 ccRCC, 1 papillary cancer type II, and 1 chromofobe type) were revealed in tumors with strong or moderate PSMA combined scores (3–4 and 5–6). In ccRCC tissue samples, PSMA expression was strong to moderate in 20/22 cases. The SUVmax values correlated to the intensity of PSMA expression which were assessed using IHC (<i>p</i> = 0.01), especially in the ccRCC subgroup (<i>p</i> = 0.009). Median survival was significantly higher in patients with negative PSMA-PET/CT (48 months) compared to patients with a positive scan (24 months, <i>p</i>= 0.001). SUVmax ≥ 7.4 provides discrimination of patients with a poor prognosis. Results of PSMA-PET/CT changed treatment planning. Conclusions: in renal cancer, positive PSMA-PET/CT is strongly correlated to the intensity of PSMA expression on immunohistochemistry in both ccRCC and chromophobe cancer. PSMA-PET/CT signal predicts a poor prognosis confirming its potential as an aggressiveness biomarker and providing paramount additional information influencing patient management.
format Article
id doaj-art-99ef8173030e4625a19ee8e4e94461ba
institution Directory of Open Access Journals
issn 2075-4418
language English
publishDate 2023-09-01
publisher MDPI AG
record_format Article
spelling doaj-art-99ef8173030e4625a19ee8e4e94461ba2025-08-19T22:45:18ZengMDPI AGDiagnostics2075-44182023-09-011319308210.3390/diagnostics13193082High Prognostic Value of <sup>68</sup>Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by ImmunohistochemistryDonatello Gasparro0Maura Scarlattei1Enrico Maria Silini2Silvia Migliari3Giorgio Baldari4Veronica Cervati5Tiziano Graziani6Nicoletta Campanini7Umberto Maestroni8Livia Ruffini9Oncology Division, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyNuclear Medicine Division, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyPathology Division, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyNuclear Medicine Division, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyNuclear Medicine Division, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyNuclear Medicine Division, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyNuclear Medicine Division, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyPathology Division, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyUrology Division, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyNuclear Medicine Division, Azienda Ospedaliero-Universitaria di Parma, 43126 Parma, ItalyIn oligo-metastatic renal cell carcinoma (RCC), neither computed tomography (CT) nor bone scan is sensitive enough to detect small tumor deposits hampering early treatment and potential cure. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in the neo-vasculature of numerous malignant neoplasms, including RCC, that can be targeted by positron emission tomography (PET) using PSMA-targeting radioligands. Our aim was to investigate whether PSMA-expression patterns of renal cancer in the primary tumor or metastatic lesions on immunohistochemistry (IHC) are associated with PET/CT findings using [<sup>68</sup>Ga]-PSMA-HBED-CC (PSMA-PET/CT). We then analyzed the predictive and prognostic role of the PSMA-PET/CT signal. In this retrospective single-center study we included patients with renal cancer submitted to PSMA-PET/CT for staging or restaging, with tumor specimens available for PSMA-IHC. Clinical information (age, tumor type, and grade) and IHC results from the primary tumor or metastases were collected. The intensity of PSMA expression at IHC was scored into four categories: 0: none; 1: weak; 2: moderate; 3: strong. PSMA expression was also graded according to the proportion of vessels involved (PSMA%) into four categories: 0: none; 1: 1–25%; 2: 25–50%; 3: >50%. The intensity of PSMA expression and PSMA% were combined in a three-grade score: 0–2 absent or mildly positive, 3–4 moderately positive, and 5–6 strongly positive. PSMA scores were used for correlation with PSMA-PET/CT results. Results: IHC and PET scans were available for the analysis in 26 patients (22 ccRCC, 2 papillary RCC, 1 chromophobe, 1 “not otherwise specified” RCC)<b>.</b> PSMA-PET/CT was positive in 17 (65%) and negative in 9 patients (35%). The mean and median SUVmax in the target lesion were 34.1 and 24.9, respectively. Reporter agreement was very high for both distant metastasis location and local recurrence (kappa 1, 100%). PSMA-PET detected more lesions than conventional imaging and revealed unknown metastases in 4 patients. Bone involvement, extension, and lesion number were greater than in the CT scan (median lesion number on PET/CT 3.5). The IHC PSMA score was concordant in primary tumors and metastases. All positive PSMA-PET/CT results (15/22 ccRCC, 1 papillary cancer type II, and 1 chromofobe type) were revealed in tumors with strong or moderate PSMA combined scores (3–4 and 5–6). In ccRCC tissue samples, PSMA expression was strong to moderate in 20/22 cases. The SUVmax values correlated to the intensity of PSMA expression which were assessed using IHC (<i>p</i> = 0.01), especially in the ccRCC subgroup (<i>p</i> = 0.009). Median survival was significantly higher in patients with negative PSMA-PET/CT (48 months) compared to patients with a positive scan (24 months, <i>p</i>= 0.001). SUVmax ≥ 7.4 provides discrimination of patients with a poor prognosis. Results of PSMA-PET/CT changed treatment planning. Conclusions: in renal cancer, positive PSMA-PET/CT is strongly correlated to the intensity of PSMA expression on immunohistochemistry in both ccRCC and chromophobe cancer. PSMA-PET/CT signal predicts a poor prognosis confirming its potential as an aggressiveness biomarker and providing paramount additional information influencing patient management.https://www.mdpi.com/2075-4418/13/19/3082renal-cell carcinoma (RCC)PSMA expressionPET-CT
spellingShingle Donatello Gasparro
Maura Scarlattei
Enrico Maria Silini
Silvia Migliari
Giorgio Baldari
Veronica Cervati
Tiziano Graziani
Nicoletta Campanini
Umberto Maestroni
Livia Ruffini
High Prognostic Value of <sup>68</sup>Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry
renal-cell carcinoma (RCC)
PSMA expression
PET-CT
title High Prognostic Value of <sup>68</sup>Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry
title_full High Prognostic Value of <sup>68</sup>Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry
title_fullStr High Prognostic Value of <sup>68</sup>Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry
title_full_unstemmed High Prognostic Value of <sup>68</sup>Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry
title_short High Prognostic Value of <sup>68</sup>Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry
title_sort high prognostic value of sup 68 sup ga psma pet ct in renal cell carcinoma and association with psma expression assessed by immunohistochemistry
topic renal-cell carcinoma (RCC)
PSMA expression
PET-CT
url https://www.mdpi.com/2075-4418/13/19/3082
work_keys_str_mv AT donatellogasparro highprognosticvalueofsup68supgapsmapetctinrenalcellcarcinomaandassociationwithpsmaexpressionassessedbyimmunohistochemistry
AT maurascarlattei highprognosticvalueofsup68supgapsmapetctinrenalcellcarcinomaandassociationwithpsmaexpressionassessedbyimmunohistochemistry
AT enricomariasilini highprognosticvalueofsup68supgapsmapetctinrenalcellcarcinomaandassociationwithpsmaexpressionassessedbyimmunohistochemistry
AT silviamigliari highprognosticvalueofsup68supgapsmapetctinrenalcellcarcinomaandassociationwithpsmaexpressionassessedbyimmunohistochemistry
AT giorgiobaldari highprognosticvalueofsup68supgapsmapetctinrenalcellcarcinomaandassociationwithpsmaexpressionassessedbyimmunohistochemistry
AT veronicacervati highprognosticvalueofsup68supgapsmapetctinrenalcellcarcinomaandassociationwithpsmaexpressionassessedbyimmunohistochemistry
AT tizianograziani highprognosticvalueofsup68supgapsmapetctinrenalcellcarcinomaandassociationwithpsmaexpressionassessedbyimmunohistochemistry
AT nicolettacampanini highprognosticvalueofsup68supgapsmapetctinrenalcellcarcinomaandassociationwithpsmaexpressionassessedbyimmunohistochemistry
AT umbertomaestroni highprognosticvalueofsup68supgapsmapetctinrenalcellcarcinomaandassociationwithpsmaexpressionassessedbyimmunohistochemistry
AT liviaruffini highprognosticvalueofsup68supgapsmapetctinrenalcellcarcinomaandassociationwithpsmaexpressionassessedbyimmunohistochemistry